Lung Cancer Resource Center

diamond, SCLC, lung cancer, cancer, asbestos, exposure, mold, Dustin Diamond, Known As Screech on ‘Saved By The Bell,’ Starts Stage 4 Lung Cancer Treatment—What Does This Mean?

Dustin Diamond Dead From Lung Cancer at 44. What Is The Prognosis for SCLC?

Dustin Diamond, who rose to fame in the 1990s for his role as Samuel “Screech” Powers on the hit television show “Saved By The...

Lung Cancer Disparities Highlighted Among Key Groups

Among patients with lung cancer, disparities exist with race, gender, sexual orientation, and economic status in virtual every country worldwide, according to several leading...
diamond, SCLC, lung cancer, cancer, asbestos, exposure, mold, Dustin Diamond, Known As Screech on ‘Saved By The Bell,’ Starts Stage 4 Lung Cancer Treatment—What Does This Mean?

Did Dustin Diamond Get Lung Cancer From Staying in Cheap Motels?

Dustin Diamond is questioning what caused him to develop lung cancer and is reportedly speculating whether it may be the result of his frequent...
diamond, SCLC, lung cancer, cancer, asbestos, exposure, mold, Dustin Diamond, Known As Screech on ‘Saved By The Bell,’ Starts Stage 4 Lung Cancer Treatment—What Does This Mean?

Dustin Diamond, Known As Screech on ‘Saved By The Bell,’ Starts Stage 4 Lung...

Dustin Diamond, known best for his portrayal of Screech Powers on the hit 1990’s show “Saved By The Bell,” was recently diagnosed with stage...
eligibility, ORLM, Pegilodecakin with Pembrolizumab or Nivolumab Effectively Treats Tumors

New Guidelines for Lung Cancer Improve Eligibility Among Minorities, But Don’t Close Racial Gap

An analysis of the latest US Preventive Services Task Force (USPSTF) lung cancer screening guideline for screening eligibility found that while improvements were made...
video

Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC

Verastem Oncology recently announced the initiation of the second phase 2 registration-directed clinical trial from its RAMP (Raf And Mek Program). The study, RAMP...
Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations

Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations

TUESDAY, Dec. 22, 2020 (HealthDay News) -- Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal...

Curated Journal Reading List